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Abstract. Multiple drug resistance remains an unsolved 
problem in cancer therapy. A previous study has demonstrated 
that the chemotherapeutic drug doxorubicin (Dox) induced 
upregulation of P-glycoprotein in endothelial cells, resulting in 
a 20‑fold increase in drug resistance and reduced efficiency of 
doxorubicin treatment in a mouse tumor model. In the present 
study, the cross-resistance and sensitivity of HMECd1 and 
HMECd2 established cell lines to anti-angiogenic drugs, 
particularly sunitinib, was explored. The results revealed that 
Dox treatment induced a significant increase in the breast 
cancer resistance protein (ABCG2) gene transcription and 
protein expression. This increase gave rise to a 4- to 5-fold 
increase in the half maximal inhibitory concentration of the 
HMECd1 and HMECd2 cells in response to sunitinib treat-
ment in vitro. Functionally, the role of ABCG2 in the resistance 
to sunitinib was confirmed by the use of the ABCG2 inhibi-
tors fumitremorgin C and diethylstilbestrol, which blocked 
cell resistance. The present study indicates that endothelial 
cells exhibit cross-resistance between cytotoxic drugs and 
anti-angiogenic drugs. This suggests that multiple drug resis-
tance induced by chemotherapy in endothelial cells may affect 
the efficiency of anti‑angiogenic drugs.
Introduction 
Cancer development depends on a complex tissue environment 
for growth and metastasis (1). It is now widely recognized 
that immune reaction and vascular growth support tumor 
growth (2). Since that breakthrough, anti-angiogenic therapy 
has been successfully introduced in clinical cancer therapy to 
starve tumors (3-6). 
Theoretically, using anti-angiogenic agents to block 
factors crucial to tumor angiogenesis should offer several 
advantages over conventional chemotherapy agents. First, 
anti-angiogenic therapy can treat all solid tumors without 
being restricted to a specific tumor type. Second, as 
anti-angiogenic therapy targets the endothelial cells within 
the tumor vasculature, the agents within the blood stream 
directly affect the targeted cells, without penetration of the 
tumor being necessary. Furthermore, anti-angiogenic drugs 
are not expected to give rise to drug resistance as they do 
not target the highly mutable cancer cell population, but 
rather the more genetically stable endothelial cells (7,8). 
Anti-angiogenic therapy should thus allow for prolonged 
treatment with anti-angiogenic drugs, without giving rise to 
resistance. 
Currently, hundreds of clinical tr ials involving 
anti-angiogenic agents are underway. Despite the initial 
promising performance of anti-angiogenic drugs in clinical 
trials, anti-angiogenesis therapy faces numerous challenges, 
including inherent and acquired resistance. The majority of 
cancer patients eventually demonstrate a lack of response to 
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anti-angiogenic therapy while on the treatment regimen (4-6). 
Studies using clinical and preclinical models have documented 
the involvement of certain molecular and cellular mecha-
nisms (9-11). At present, the proposed mechanisms include 
alternative angiogenic pathways, such as selective pressure of 
hypoxia, cancer stem cells, autophagy, recruitment of vascular 
progenitors and modulators, and tumor dormancy (11). In 
particular, previous studies indicate that acquired drug resis-
tance in tumor endothelial cells is involved in drug resistance 
in cancer patients (12,13).
Multidrug resistance is considered a major obstacle 
for successful chemotherapy in the treatment of cancer. 
Chemotherapy loses effectiveness over time. One reason is 
the drug resistance caused by the compensatory response 
of tumor cells (10,14). One of the main underlying mecha-
nisms for multidrug resistance in cancer chemotherapy is the 
overproduction of ATP-binding cassette (ABC) transporter, 
which serves as a pump to remove toxic drugs from tumor 
cells, thus rendering the tumor cells resistant to multiple 
chemotherapeutic drugs. 
Clinical studies of human cancer have found a correla-
tion between P-glycoprotein (P-gp) overexpression in tumor 
tissues with decreased survival and poor prognosis (14). 
High P-gp expression has been found in tumor endothelial 
cells, likely in response to vascular endothelial growth factor 
stimulation (15). We have also shown that the chemothera-
peutic agent doxorubicin (Dox) induces high levels of P-gp 
in endothelial cells (12). Our previous study established two 
endothelial cell lines, HMECd1 and HMECd2, that exhibited 
high drug resistance to doxorubicin (Dox) induction in vitro. 
These two stabilized sub cell lines demonstrated 15- and 
24-fold increases in resistance to Dox. Acquired drug resis-
tance in endothelial cells was also revealed to attenuate the 
efficacy of doxorubicin treatment in a mouse tumor model. 
Dox-induced drug resistance in these endothelial cells was 
predominantly due to MDR1/P-gp upregulation. Inhibiting 
the activity of P-gp could reverse the resistance of endothelial 
cells. Furthermore, the drug resistance of endothelial cells 
attenuated the efficacy of doxorubicin treatment in vivo (12). 
This previous study indicated that the acquired drug resis-
tance of tumor vessels plays a critical role in cancer therapy. 
The breast cancer resistance protein (ABCG2) is another 
ABC transporter that has been identified as a molecular 
cause of multidrug resistance in diverse cancer cells (16,17). 
As an efflux transporter for xenobiotics and unwanted toxic 
compounds, ABCG2 has been characterized as an important 
component of self-defense systems in organisms (18). In the 
brain microvasculature, ABCG2 is located on the luminal 
surface of microvessel endothelium and hence may constitute 
an important component of the blood-brain barrier (19). 
Sunitinib is an oral multi-targeted receptor tyrosine 
kinase inhibitor of vascular endothelial growth-factor recep-
tors (20,21). Currently, sunitinib is used to treat advanced 
or metastatic renal cell carcinoma, gastrointestinal stromal 
tumors, meningioma and pancreatic neuroendocrine tumors. 
Clinical trials of combined sunitinib therapy with chemotherapy 
are ongoing (22-24). Patient resistance to sunitinib treatment 
has been reported (11,25,26). The aim of the present study 
was to investigate the risk of acquired and cross-resistance to 
anti-angiogenic drugs in endothelial cells during chemotherapy. 
Materials and methods
Materials. Mouse monoclonal anti-P-gp, anti-ABCG2 and 
anti-MRP1 antibodies were purchased from Abcam (Cambridge, 
UK). Sunitinib was obtained from Pfizer, Inc. (New York, NY, 
USA). Doxorubicin chlorhydrate was purchased from Amersham 
Pharmacia Biotech, Inc. (Uppsala, Sweden). Verapamil was 
obtained from Calbiochem (Billerica, MA, USA). Paclitaxel, 
vinblastine, cyclosporine A, fumitremorgin C, diethylstilbestrol 
and MK571 were purchased from Sigma-Aldrich (Saint Louis, 
MO, USA).
Cell culture. Parental and resistant HMEC-1 cell lines, 
obtained from Dr TL Lawley (Department of Dermatology, 
Atlanta, GA, USA), were cultured in MCDB-131 medium 
supplemented with 10% fetal calf serum (FCS), 2 mM 
L-glutamine, 10 ng/ml epidermal growth factor, 1 µg/ml 
hydrocortisone, 100 units/ml penicillin, and 100 µg/ml strep-
tomycin, as described elsewhere (12,27). Dox-resistant 
HMEC cells were obtained by continuously exposing 
cells to increasing concentrations of Dox, between 
0.001 and 0.24 µg/ml, over a 12-week period, as previously 
described (12). Two sub cell lines of HMEC-1 cells were 
collected, HMECd1 cells were maintained in a culture with 
0.08 µg/ml Dox and HMECd2 cells were maintained in 
0.24 µg/ml Dox. No mutagenic agents were used to establish 
these Dox-resistant HMEC cells. To observe the reversibility 
of the drug resistance of the cells, Dox was withdrawn from 
the culture medium of HMECd1 and HMECd2 cells. All cell 
types were digested with trypsin-EDTA once or twice a week 
and cultured in a 37˚C incubator with a 100% humidified 
atmosphere of 5% CO2.
MTS cell proliferation assay. Cell viability was determined using 
MTS cell proliferation assay (Promega, Madison, WI, USA). 
Cells grew to a confluence of 90% in 75 cm2 cell culture flasks 
and were passed into 96-well plates (7,500 cells/well). Each well 
contained 100 µl of culture medium, which was supplemented 
with various concentrations of drugs or with a concentration of 
dimethyl sulfoxide as a control. Following incubation for either 
24, 48 or 72 h, 20 µl of the MTS reagent was added to each well 
and the plate was placed in the 5% CO2 incubator at 37˚C for an 
additional 2 h. The optical density (OD) was then read at 492 nm 
using a microplate reader (Labsystems Multiskan MS; MTX Lab 
Systems Inc.,  Vienna, VA, USA). The half maximal inhibitory 
concentration (IC50) values were defined as the concentration of 
drug producing 50% inhibition of cell growth and the resistance 
index corresponding to the ratio of IC50 values between the 
resistant and parental cell lines. Experiments were performed in 
triplicate and repeated at least three times.
Blocking effect assay. The experiments used ABCG2 inhibi-
tors, 5 µM fumitremorgin C and 0.5 µM diethylstilbestrol, 
and P-gp inhibitors, 2.5 µM cyclosporine A, 1 µM verapamil 
and 5 µM MK571. Following incubation for 48 or 72 h, the 
cell viability was assessed using an MTS assay. The reversal 
fold (RF) values, a measure of the potency of reversal, 
were obtained by fitting the data to RF = IC50 of cytotoxic 
drug alone / IC50 of cytotoxic drug in the presence of a 
modulator (28).
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Evaluation of mRNA expression via quantitative poly‑
merase chain reaction (qPCR). The HMEC-1, HMECd1 and 
HMECd2 cells were treated with 2.5 µM cyclosporine A, 
1 µM verapamil, 5 µM fumitremorgin C, 0.5 µM diethylstil-
bestrol or 5 µM MK571 for 24 h. Subsequent to incubation, 
the treated and non-treated cells were harvested, and total 
RNA was prepared using the SV total RNA isolation system 
kit (Promega). The purity of total RNA was checked by a ratio 
of A260/A280 (>1.9). Total RNA (50 ng) was used to synthesize 
the first‑strand cDNA in a 20‑µl reaction solution using the 
GoScript Reverse Transcription System kit (Promega). Then, 
2 µl of cDNA was used for qPCR in triplicates using a TaqMan® 
gene expression assay (Applied Biosystems, Foster City, 
CA, USA) and the primers for P-gp (Hs01067802_m1), 
ABCG2 (Hs01053790_m1), multidrug resistance protein 
(MRP) 1 (Hs00219905_m1), as well as the primers for TATA 
box binding protein (TBP) as controls (Hs99999910_m1; 
Applied Biosystems). qPCR was performed by 10 min of 
initial denaturation followed by 44 cycles of 15 sec at 95˚C 
and 60 sec at 60˚C in a BioRad CFX96® Real‑time system 
(Bio-Rad Laboratories, Hercules, CA, USA). The ΔCt method 
was used to analyze the qPCR results, and TBP was used as 
an internal control for mRNA-level normalization. 
Evaluation of protein expression using western blot analysis. 
Western blot analysis was performed on whole-cell lysates by 
incubating the cells in the lysis buffer (10 mM Tris pH 6.8, 
1 mM EDTA, 10% Nonidet P-40, 1 mM phenylmethane-
sulfonyl fluoride, 0.1% SDS) on ice for 30 min. Cell debris 
was removed by centrifugation at 16,000 x g for 10 min. 
Protein concentration was determined by bicinchoninic 
acid protein assay (Thermo Fisher Scientific, Waltham, 
MA, USA). A 50 µg protein sample from each sample 
was loaded on an 8% SDS-PAGE gel, and the protein was 
transferred to a polyvinylidene fluoride membrane using 
the iBlot dry blotting system (Invitrogen, Carlsbad, CA, 
USA). The membranes were blocked with 5% non-fat dry 
milk for 1 h and incubated with either anti-P-gp (ab-3364; 
1:20; Abcam), anti-MRP1 (ab-32574; 1:250; Abcam) or 
anti‑ABCG2 antibodies (ab‑3380; 1:100; Abcam) at 4˚C over-
night. The membranes were then washed with a Tris buffered 
saline with Tween 20 buffer for 1 h and incubated with the 
appropriate horseradish peroxidase-conjugated secondary 
antibodies (Invitrogen), diluted in blocking buffer, for 1 h at 
room temperature. Subsequent to washing, western blotting 
luminol reagent (Santa Cruz Biotechnology, Inc., Dallas, 
TX, USA) was added to the membranes and the chemilu-
minescence was recorded using a Fuji LAS-3000 system 
(Fujifilm, Tokyo, Japan). The membranes were then treated 
with an antibody-stripping buffer (Gene Bio-Application Ltd., 
Kfar Hanagid, Israel) and incubated with anti-actin antibody 
(1:4,000 dilution; Sigma-Aldrich) as a control. 
Statistical analyses. The data were analyzed using one-way 
analysis of variance and Mann-Whitney U tests, as appro-
priate. The qPCR data is presented as the mean ± standard 
error of the mean. The remaining data is presented as the 
mean ± standard deviation. P≤0.05 was considered to indicate 
a statistically significant difference. 
Results
Endothelial cells resistant to anti‑angiogenesis drugs. 
To address the question of the response of HMECd1 and 
HMECd2 to the anti-angiogenic drugs, the efficacy of suni-
tinib was tested in vitro. The first experiment with MTS 
assay revealed that HMEC-1 cells are initially sensitive to 
sunitinib treatment. However, compared with their parental 
cells, HMECd1 and HMECd2 cells revealed 2.1- and 
4.51-fold increases in drug-resistance to sunitinib (Table I). 
The increase in sunitinib resistance accompanied the increase 
in Dox resistance (Table I). This observation corresponded 
with the typical multi-drug resistance of endothelial cells in 
response to Dox induction. 
ABCG2 and P‑gp are predominantly expressed in the resis‑
tant endothelial cells. qPCR was used to measure changes in 
drug efflux transporter gene expression in the Dox‑induced 
resistant endothelial cells. The P-gp and ABCG2 expression 
in HMECd1 and HMECd2 cells increased significantly 
compared to parental cells (1.41- and 1.68-fold for ABCG2; 
3.4‑ and 7.2‑fold for P‑gp; Fig. 1). To evaluate the influence 
of the ABC transporter blockers used in the study of gene 
expression, the changes in P-gp, ABCG2 and MRP1 mRNA 
levels in the presence of the inhibitors of the three transporters 
were quantified, respectively. 
There was no significant change in the gene expression of 
P-gp and ABCG2 in HMECd1 and HMECd2 cells when the 
function of P-gp or ABCG2 was blocked (Fig. 1A and B). The 
qPCR results also indicated that MRP1 was not induced in 
HMECd1 and HMECd2 cells (data not shown). Western blot-
ting revealed approximately two- to four-fold increases in the 
Table I. Dox-induced cross-resistance to Dox and sunitinib in HMEC-1 endothelial cells.
 HMEC-1 HMECd1 HMECd2
 ----------------------- ----------------------------------------------------------- -------------------------------------------------------------
Agents IC50, µM IC50, µM RI IC50, µM RI
Sunitinib 4.271±0.501 8.585±0.642   2.01a 19.252±0.855 4.51a
Doxorubicin 0.056±0.006 0.812±0.050 14.50a   1.209±0.085 21.60a
The cells were treated as described in the main text and tested with MTS assay. The RI was determined as the IC50 of Dox-treated HMECd1 or 
HMECd2 cells divided by the IC50 of Dox-treated HMEC-1 cells. aP<0.05, vs. HMEC-1 cells. Dox, doxorubicin; RI, resistance index; IC50, 
half maximal inhibitory concentration.
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ABCG2 protein expression of the cells. Withdrawal of Dox 
in the culture media for more than three weeks resulted in a 
decrease in P-gp and ABCG2 expression in HMECd1 (Hd1r)
and HMECd2 (Hd2r) cells (Fig. 1). This indicated that the 
P-gp and ABCG2 expression was reversible.
Blocking ABCG2 attenuates the resistance of Dox‑induced 
endothelial cells to sunitinib. The survival of HMECd1 and 
HMECd2 cells was examined subsequent to sunitinib treat-
ment in the presence of the P-gp blockers cyclosporine A and 
verapamil, or in the presence of the ABCG2 blockers fumitrem-
orgin C and diethylstilbestrol. The results revealed that only the 
blockade of ABCG2 function significantly restored the sensi-
tivity of Dox-induced of endothelial cells to sunitinib (Table II). 
By contrast, the P-gp inhibitors demonstrated no such effect. 
Discussion
Drug resistance remains a difficult, unsolved issue in cancer 
therapy. Since the start of the use of anti-angiogenic therapy, 
Table II. Effect of P-gp inhibitors and ABCG2 inhibitors on sunitinib resistance in HMEC-1 cells.
 HMEC-1 HMECd1 HMECd2
 ------------------------ ---------------------------------------------------------------------- ------------------------------------------------------------------------
Agents IC50, µM IC50, µM RI RF IC50, µM RI RF
Sunitinib 4.271±0.501 8.585±0.642   2.01a 1.00 19.252±0.855   4.51a 1.00
+ 5 µM fumC 4.359±0.622 5.886±0.417   1.35b 1.45   6.163±0.062   1.41b 3.12
+ 0.5 µM die 4.204±0.468 6.259±0.541   1.48b 1.37   7.159±0.057   1.70b 2.69
+ 1 µM vrp  4.952±0.875 9.159±0.356 1.84 0.94 17.659±0.526 3.57 1.09
+ 2.5 µM cysA 4.098±0.562 8.871±0.459 2.16 0.97 20.348±0.328 4.97 0.95
The cells were treated as described in the main text and tested with MTS assay. The RI was determined by: IC50 of Dox-treated HMECd1 or 
HMECd2 cells / IC50 of Dox-treated HMEC-1 cells. The RF was calculated by: IC50 of Dox-treated HMECd1 or HMECd2 cells / IC50 of the 
same cell line treated by sunitinib + P-gp or ABCG2 inhibitors. aP<0.05, vs. HMEC-1 cells; bP<0.05, vs. HMECd1 and HMECd2 cells without 
P-gp or ABCG2 inhibitors. P-gp, P-glycoprotein; ABCG2, breast cancer resistance protein; RI, resistance index; RF, resistance fold; IC50, half 
maximal inhibitory concentration; Dox, doxorubicin; fumC, fumitremorgin C; die, diethylstilbestrol; vrp, verapamil; cysA, cyclosporine A.
Figure 1. Induced ABCG2 expression in HMEC-1 endothelial cells. (A) qPCR (primer, Hs01053790_m1) of ABCG2 mRNA levels in treated or non-treated 
HMEC-1, HMECd1, HMECd2, HMECd1r and HMECd2r cells cultured without Dox for three weeks. Sunitinib, fumitremorgin C and diethylstilbestrol were 
used to treat the cells. The results were obtained from three independent experiments. *P<0.05, vs. non-treated cells. (B) qPCR (primer, Hs01067802_m1) of P-gp 
mRNA levels in treated or non-treated HMEC-1, HMECd1, HMECd2 and HMECd2r cells. Sunitinib, fumitremorgin C, and diethylstilbestrol were used to treat 
the cells. The results were obtained from three independent experiments. *P<0.05 and **P<0.01, vs. non-treated cells. (C) Western blot analysis of ABCG2 levels in 
HMEC-1, HMECd2 and HMECd2r cells. The data for the ratio were obtained from three repeated blots. *P<0.05, vs. the control and Hd2r cells. C, HMEC-1; Hd1, 
HMECd1; Hd2, HMECd2; Hd1r, HMECd1r; Hd2r, HMECd2r; Su, sunitinib; F, fumitremorgin C; D, diethylstilbestrol; ABCG2, breast cancer resistance protein.
  A   B
  C
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it was expected to be an exception to drug resistance (7,8). 
However, primary or acquired drug resistance was soon 
reported in anti-angiogenic therapy and the mechanisms of 
that resistance have been periodically reviewed (9-11). In a 
previous study, it was demonstrated that doxorubicin success-
fully induced multiple resistance in endothelial cells (12). In 
the present study, the response of two stabilized endothelial 
cell lines, HMECd1 and HMECd2, to the anti-angiogenesis 
drug sunitinib was evaluated.
The present study provides evidence that ABCG2 medi-
ates the substrate efflux of sunitinib in endothelial cells. The 
present study demonstrated that, in addition to P-gp upregula-
tion, ABCG2 expression was upregulated in HMECd1 and 
HMEd2 cells. The ABCG2 protein levels, revealed by western 
blot analysis, were found to possess a two- to four-fold increase 
in HMECd1 and HMECd2 cells compared with their parental 
cells. Similarly, qPCR revealed 1.41- and 1.68-fold increases 
in ABCG2 gene expression in the HMECd1 and HMECd2 
cells. It was revealed that P-gp was not involved in sunitinib 
resistance as two inhibitors of P-gp, cyclosporine A and vera-
pamil, failed to reverse sunitinib resistance in HMECd1 and 
HMEC2. By contrast, the blockade of ABCG2 activity by 
fumitremorgin C and diethylstilbestrol greatly inhibited the 
capacity of the cells for sunitinib resistance. These results 
indicate that ABCG2 plays a major functional role in the resis-
tance of HMECd1 and HMEC2 endothelial cells to sunitinib 
in vitro. The present results were in agreement with previous 
reports that revealed the involvement of ABCG2 in the resis-
tance of cells to sunitinib treatment, although the involvement 
of P-gp has not been excluded in in vivo studies (29-31). As 
resistance to sunitinib in endothelial cells can be induced by 
Dox, potential cross-resistance in combined therapy that uses 
chemotherapy and targeted therapy may occur in clinical trials. 
Cross-resistance in cancer therapy was observed in clinical 
settings >50 years ago (32,33). Currently, as the combined use 
of chemotherapy and anti-angiogenic drugs develops rapidly, 
it is particularly important to explore cross-resistance. Indeed, 
clinical trials evaluating the combined use of targeted therapy 
and chemotherapy are extremely dynamic. For example, 
>10 chemotherapy drugs, including cisplatin, 5‑fluoroutacil 
and paclitaxel are currently being explored in combination 
with sunitinib in clinical studies (22-24). Furthermore, in 
the present study, resistance of the endothelial cells to other 
agents used in targeted therapy was observed (data not shown). 
Ongoing clinical trials comprise numerous anti-angiogenic 
drugs (34,35). These trials require additional knowledge about 
the occurrence of cross-resistance, not only in tumor cells but 
also in endothelial cells. 
Cross-resistance is complex as each ABC transporter can 
induce the efflux of a panel of chemical molecules based on 
physical affinity (18). Furthermore, a drug that consists of a 
single chemical can induce the upregulation of more than one 
ABC protein, as described in previous studies (12,20). During 
the establishment and optimization of a clinical therapeutic 
protocol with the provided therapeutic targets, it would be 
beneficial to evaluate and consider the potential risk of the 
development of cross-resistance to the treatment drugs. From 
this standpoint, additional effort would aid in the optimiza-
tion of the combined use of chemotherapeutic agents and 
anti-angiogenic agents. Notably, as cross-resistance may occur 
in tumor and endothelial cells, it can also be speculated that 
the biological properties of drug resistance in these two types 
of cells may exhibit differences. 
Since anti-angiogenic agents have been used clinically, 
patient resistance to anti-angiogenic drugs has been reported 
and analyzed frequently. Proposed mechanisms of resistance 
include alternative angiogenic escape factors, an increase in 
the stem cell population that is resistant to hypoxia, the selec-
tion of cells with acquired metastatic and invasive potential by 
hypoxia and tumor cell dormancy (11). Avoiding cross-resis-
tance is expected to contribute to the further improvement of 
anticancer therapy, together with strategies that target multiple 
pathways involved in angiogenesis and resistance. 
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